Akèy › Kansè Endomèt › Tennessee
Etid klinik pou Kansè Endomèt nan Tennessee
41 etid pou Kansè Endomèt ap chèche patisipan nan sit nan Tennessee.
Vil nan Tennessee
Tèks ofisyèl etid la (Anglè)
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
- Baptist Memorial Hospital and Cancer Center-Collierville, Collierville
- Regional Cancer Center at Johnson City Medical Center, Johnson City
- Ballad Health Cancer Care - Kingsport, Kingsport
- ak 3 plis
Ap rekriteFaz 2
Tout laj · Tout sèks · Mizajou Oct 2, 2026 · NCT05564377The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Sarah Cannon Research Institute, Nashville
Ap rekriteFaz 1/2
Laj 12 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT04585750A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
- Tennessee Oncology, Nashville
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT06270706Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
- Vanderbilt-Ingram Cancer Center Cool Springs, Franklin
- Vanderbilt Breast Center at One Hundred Oaks, Nashville
- Vanderbilt University/Ingram Cancer Center, Nashville
Ap rekriteFaz 3
Laj 18 ak plis · Fanm · Mizajou Oct 2, 2026 · NCT07198074A Phase 1 Study of the Safety and Tolerability of CTX-10726
- SCRI Oncology Partners, Nashville
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT07419841A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
- SCRI Oncology Partners, Nashville
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT06760819A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
- Sarah Cannon Research Institute (SCRI), Nashville
Ap rekriteFaz 1
Laj 19 ak plis · Tout sèks · Mizajou Oct 1, 2026 · NCT06586957A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
- SCRI Oncology Partners, Nashville
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Oct 1, 2026 · NCT06172478DESTINY-PANTUMOUR04
- Research Site, Nashville
Ap rekriteEtid obsèvasyon
Laj 18 a 130 · Tout sèks · Mizajou Sep 25, 2026 · NCT07124000Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
- Research Site, Nashville
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06218914Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
- Research Site, Nashville
Ap rekriteFaz 2
Laj 18 a 130 · Tout sèks · Mizajou Sep 23, 2026 · NCT05489211Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
- Sarah Cannon Research Institue, Nashville
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT06128551Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
- Sarah Cannon - Tennessee Oncology, Nashville
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 21, 2026 · NCT05983432A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
- Erlanger Medical Center ( Site 5009), Chattanooga
Ap rekriteFaz 3
Laj 18 ak plis · Fanm · Mizajou Sep 17, 2026 · NCT06952504A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
- Sarah Cannon Nashville, Nashville
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 17, 2026 · NCT07109726A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors
- GSK Investigational Site, Nashville
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 16, 2026 · NCT07213609Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
- Sarah Cannon Research Institute, Nashville
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 10, 2026 · NCT06293898Phase 1 Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of ARR-002 in Advanced or Metastatic Ovarian or Endometrial Cancer.
- Sarah Cannon Research Institute, Nashville
Ap rekriteFaz 1
Laj 18 ak plis · Fanm · Mizajou Sep 3, 2026 · NCT07755436A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors
- Vanderbilt-Ingram Cancer Center, Nashville
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 3, 2026 · NCT06515613Endometrial Cancer Vaginal Fluid Specimen Collection Study
- Murfreesboro Medical Clinic, Murfreesboro
- IC Research, Murfreesboro
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Fanm · Mizajou Aug 27, 2026 · NCT07544680A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors
- SCRI Oncology Partners - Nashville, Nashville
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 26, 2026 · NCT07383506Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
- SCRI Oncology Partners, Nashville
Ap rekriteFaz 1
Laj 15 ak plis · Tout sèks · Mizajou Aug 25, 2026 · NCT06276491Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- Saint Jude Children's Research Hospital, Memphis
Ap rekriteFaz 1/2
12 Months – 30 Years · Tout sèks · Mizajou Aug 25, 2026 · NCT04851119A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
- Normunity Investigational Site, Nashville
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 18, 2026 · NCT07182149FOG-001 in Locally Advanced or Metastatic Solid Tumors
- Sarah Cannon Research Institute, Nashville
- Vanderbilt Ingram Cancer Center, Nashville
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Aug 17, 2026 · NCT05919264A Study of PHST001 in Advanced Solid Tumors
- Sarah Cannon Research Institute (SCRI) Oncology Partners, Nashville
- Vanderbilt-Ingram Cancer Center, Nashville
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 12, 2026 · NCT06840886A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
- Sarah Cannon Research Institute Oncology Partners (SCRI-Nashville), Nashville
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Aug 11, 2026 · NCT05592626A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
- Erlanger Health, Inc, Chattanooga
- The West Clinic, Germantown
- SCRI Oncology Partners, Nashville
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Aug 5, 2026 · NCT06330064Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- Sarah Cannon Research Institute at Tennessee Oncology, Nashville
- Tennessee Oncology, Nashville
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Aug 4, 2026 · NCT05579366A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
- Tennessee Oncology, PLLC, Chattanooga
- SCRI Oncology Partners, Nashville
- Vanderbilt Medical Center, Nashville
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Jul 30, 2026 · NCT04657068Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
- Research Site, Knoxville
- Research Site, Nashville
Ap rekriteFaz 3
Laj 18 ak plis · Fanm · Mizajou Jul 29, 2026 · NCT07044336A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
- SCRI Oncology Partners, Nashville
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Jul 10, 2026 · NCT06695845First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
- The West Clinic, PLLC dba West Cancer Center, Germantown
- Sarah Cannon Research Institute, Nashville
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Jul 7, 2026 · NCT05768139A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
- Sarah Cannon Research Institute (SCRI), Nashville
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Jun 29, 2026 · NCT05377996A Study of LY4175408 in Participants With Advanced Cancer
- Sarah Cannon Research Institute, Nashville
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jun 23, 2026 · NCT07046923A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
- SCRI Oncology Partners, Nashville
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jun 18, 2026 · NCT07503808Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
- Sarah Cannon Research Institute, Nashville
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou May 6, 2026 · NCT06239194cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
- Baptist (BHMCC), Memphis
- Vanderbilt-Ingram Cancer Center, Nashville
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 40 ak plis · Tout sèks · Mizajou Jan 20, 2026 · NCT05366881SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Memphis
- Massive Bio SYNERGY-AI site, Nashville
Ap rekriteEtid obsèvasyon
Tout laj · Tout sèks · Mizajou Oct 28, 2025 · NCT03452774A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
- Tennessee Oncology, Nashville
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 24, 2025 · NCT05941507Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.